Life saving medicines could not be made fast enough to supply everyone that needs them if it wasn’t for advanced manufacturing. This is being accomplished through single-use technologies, continuous manufacturing processes, and Pharma 4.0. All of these techniques are contributing to bringing prices down, producing medicine faster, and supplying more people. “As a result, hundreds of millions of more people will soon be able to benefit from the breakthrough therapies science is giving us. Automation-powered manufacturing behind these therapies won’t make headlines—but they will help give us a better world.” Manufacturing companies can do amazing things when operating efficiently.
As advances in life sciences have begun to produce new medicines to treat a wide range of serious diseases, new therapies are generating headlines and hope. Cancers, diabetes, hepatitis, autoimmune conditions such as arthritis and other serious afflictions are all yielding to a relatively new category of immunotherapy treatments. The prospect is for more of these powerful medicines – known as “biologics,” or, in their generic versions, as “biosimilars.” Standing behind these therapies, however, and out of the limelight, are the manufacturing processes and systems needed to make these therapeutic proteins. These processes require serious innovation too. Without that kind of creativity, the new therapies – which are often exponentially more complex than more traditional medicines – simply cannot be made on the scale and with the speed, reliability, and traceability needed to fulfill their promise. Consider insulin. Tens of millions of American diabetics rely on it. But there is no way we could supply them all if the only source were stillcattle and pig pancreases, as was the case when it was first discovered. Read More